Form 4: NEOGENOMICS Director Elizabeth Floegel Reports Equity Compensation and Share Ownership Changes

NEOGENOMICS Director Elizabeth Floegel has reported the vesting of restricted stock units and the grant of new stock options and restricted stock units, aligning her interests with shareholders.

Summary

• Elizabeth Floegel, a Director at NEOGENOMICS INC (NEO), reported transactions on June 1, 2025, related to her beneficial ownership of company securities.
• 12,254 restricted stock units (RSUs) vested, converting into common stock, which were previously reported on a Form 4.
• Following the vesting, Ms. Floegel beneficially owns 23,590 shares of common stock directly.
• She was granted 16,107 new stock options with an exercise price of $7.28, exercisable from June 1, 2026, and expiring on June 1, 2035.
• Additionally, Ms. Floegel received a grant of 23,077 new restricted stock units, which will be exercisable from June 1, 2026, and once vested, the shares are not subject to expiration.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It reflects standard, expected equity compensation for a director, which aligns their interests with shareholders. There are no negative implications or unexpected events reported.

Positives

• The vesting of 12,254 restricted stock units increases Director Elizabeth Floegel's direct ownership in NEOGENOMICS, further aligning her interests with those of common shareholders.
• The grant of new stock options (16,107 units) and restricted stock units (23,077 units) serves as ongoing equity compensation, incentivizing the director's long-term commitment and performance.

Future Outlook

The document details future vesting and expiration dates for equity awards, indicating a continued long-term incentive structure for the director.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in publicly traded companies, common across various industries to align leadership incentives with shareholder value creation.

Related Party Transactions

• The transactions represent equity compensation granted by NEOGENOMICS to Elizabeth Floegel, a director of the company, which is a common form of related party transaction for executive and board compensation.

Stakeholder Impact

• Shareholders: The equity grants and vesting align the director's financial interests with shareholder value, potentially encouraging decisions that benefit the company's stock performance.

Next Steps

• The newly granted stock options will become exercisable on June 1, 2026.
• The newly granted restricted stock units will become exercisable on June 1, 2026, and will not be subject to expiration once vested.

Key Dates

Recommendation

Keywords

NEOGENOMICS, NEO, SEC Form 4, Insider Trading, Director Compensation, Restricted Stock Units, Stock Options, Equity Compensation, Beneficial Ownership